Elise M. Koch

The paper identifies a schizophrenia-specific alternative splicing program in cortical brain organoids that responds to clozapine treatment.

This paper uses genetic data from psychiatric disorders to prioritize drug targets and compounds, identifying genetic support for existing medications and opportunities for drug repurposing.

This study identifies distinct genetic overlaps between Alzheimer's and Parkinson's disease and metabolic markers, revealing disease-specific pathways involving lipid metabolism and synaptic processes.

This study identifies genetic risk loci and factors underlying clinical subtypes of bipolar disorder using GWAS and meta-analysis.

This study identifies two novel genomic loci associated with antidepressant non-response and suggests potential drugs for further validation.

The paper identifies eight drug candidates for repurposing to treat cognitive symptoms in schizophrenia, with sex-specific recommendations based on gene expression differences.

This study examines sex-specific effects of polygenic risk for schizophrenia on cognitive functioning across the lifespan in healthy individuals, finding male-specific associations.